Platinum 280 Antiblastic Response – Panel
Fluoropyrimidine 250 Antiblastic Response – Panel
OncoNext™ Liquid Scan – 15 genes: Analysis of circulating tumor DNA (ctDNA)
OncoNext™ Risk – Breast
OncoNext ™ Risk Breast is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of breast cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Ovarian
OncoNext™ Risk Ovarian is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of uterus and ovary cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Colon
OncoNext™ Risk Colon is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of colorectal cancer or Familial Adenomatous Polyposis. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Brain
OncoNext™ Risk Brain is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of brain cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – pheochromocytoma/paraganglioma
OncoNext™ Risk Pheochromocytoma / Paraganglioma is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Pheochromocytoma and Paraganglioma. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Prostate
OncoNext™ Risk Prostate is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Prostate cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
OncoNext™ Risk – Renal
OncoNext™ Risk Renal is a diagnostic test, developed by GENOMA Group, which allows you to perform a multiple genetic analysis to assess the predisposition to the development of Kidney cancer. The test, therefore, allows you to identify patients at risk of developing this neoplasia by analyzing their DNA.
